3 Shares Analysts Love: Barclays PLC, Sports Direct International Plc And Hikma Pharmaceuticals Plc

Why Barclays PLC (LON:BARC), Sports Direct International Plc (LON:SPD) and Hikma Pharmaceuticals Plc (LON:HIK) are in favour with City experts.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now, Barclays (LSE: BARC) (NYSE: BCS.US), Sports Direct (LSE: SPD) and Hikma Pharmaceuticals (LSE: HIK) are among the favoured FTSE 100 stocks of professional analysts.

Barclays

There has been much shifting in City sentiment over the past year towards the different banks that make up the Footsie’s big five. HSBC and Standard Chartered have fallen out of favour, while Lloyds and RBS have won some new friends. However, Barclays remains the City’s firm favourite — as it has been for a good few years.

Data provider Digital Look‘s sample of brokers currently shows 18 Buy recommendations, 6 Neutral and 1 Sell. So, 72% of analysts are bullish on Barclays.

Barclays’ shares are making a new 52-week high of 275p as I write, but remain undervalued on some of the measures cited by analysts. For example, the shares trade at a discount to the value of the company’s assets, having a price-to-tangible book ratio of 0.95. A current-year forecast price-to-earnings (P/E) ratio of around 12, falling to less than 10 next year on the back of strong forecast earnings growth, also looks attractive.

Two bullish brokers — Deutsche Bank and Citigroup — recently reiterated their buy recommendations and price targets of 305p and 310p, respectively.

Sports Direct

The relationship between Sports Direct founder Mike Ashley and the City has been an uneasy one, to put it mildly. Nevertheless, City analysts are fans of the business — the UK’s leading sportswear retailer — and bullish on the stock at current price levels.

According to Digital Look, 78% of analysts rate Sports Direct a Buy, and there are no Sell recommendations. Analysts at RBC Capital Markets are the latest to join the bull camp, having this week upgraded the stock to Outperform and the target price to 800p from 650p (versus a current share price of 725p). More bullish analysts have targets of 850p and 900p.

RBC points to a number of positives — including online initiatives, reduced risks around zero-hour contracts post the General Election, and lower interest and depreciation charges — and says:

“We now expect Sports Direct to achieve an earnings CAGR [compound annual growth rate] of c.13% between 2014 and 2017, up from our previous estimate of 10% and ahead of the sector average of 10.5%. This gives Sports Direct one of the lowest P/E to growth ratios in the sector. We also think Sports Direct looks better value now versus its peer group, particularly other sports chains and global peers …”

Hikma Pharmaceuticals

Hikma Pharmaceuticals — a drugs group whose revenues come largely from the US, the Middle East and North Africa — was promoted to the FTSE 100 in March, shortly after its shares hit a new high of 2,574p. Few in the City were bearish on the company during its inexorable march up to the top index, although we did see some analysts — including house broker Citigroup — move from Buy to Neutral on valuation grounds as the shares soared.

However, Hikma’s shares are now 25% off their high — currently trading at 1,940p — and the valuation is looking more attractive again. Citi has recently moved back to a Buy recommendation, saying:

“Despite our estimates being modestly below consensus, the shares at 22x 2016e/19x 2017e provide what we see as an attractive entry point in light of a five-year organic earnings compound annual growth rate of 14%”.

Like other analysts, Citi — which has a 2,400p price target on the stock — also points to Hikma’s $1bn firepower, which gives the company the ability to make earnings-enhancing acquisitions.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Barclays, Hikma Pharmaceuticals and Sports Direct International. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »